Literature DB >> 24990495

An exciting candidate therapy for sepsis: ulinastatin, a urinary protease inhibitor.

Adam Linder1, James A Russell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24990495     DOI： 10.1007/s00134-014-3366-9

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  11 in total

1.  Longitudinal studies of inter-alpha inhibitor proteins in severely septic patients: a potential clinical marker and mediator of severe sepsis.

Authors:  Steven M Opal; Yow-Pin Lim; Edward Siryaporn; Lyle L Moldawer; John P Pribble; John E Palardy; Sonia Souza
Journal:  Crit Care Med       Date:  2007-02       Impact factor: 7.598

2.  Ulinastatin: is it worth using in severe sepsis?

Authors:  Saurabh Saigal; Garima Kapoor
Journal:  Intensive Care Med       Date:  2014-05-21       Impact factor: 17.440

Review 3.  Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders.

Authors:  Ken-ichiro Inoue; Hirohisa Takano
Journal:  Expert Opin Investig Drugs       Date:  2010-04       Impact factor: 6.206

4.  [Clinical study on effects of ulinastatin on patients with systemic inflammatory response syndrome].

Authors:  Yi-ming Shao; Liang-qing Zhang; Lie-hua Deng; Hua-guo Yao
Journal:  Zhongguo Wei Zhong Bing Ji Jiu Yi Xue       Date:  2005-04

5.  [Clinical effects of ulinastatin and thymosin alpha1 on immune-modulation in septic patients].

Authors:  Lei Su; Fan-su Meng; You-qing Tang; Qiang Wen; Yun-song Liu; Li-qun Tang; Peng-kai Duan; Rui-jun Luo
Journal:  Zhongguo Wei Zhong Bing Ji Jiu Yi Xue       Date:  2009-03

6.  Treatment of patients with severe sepsis using ulinastatin and thymosin alpha1: a prospective, randomized, controlled pilot study.

Authors:  Hao Chen; Ming-yan He; Yu-min Li
Journal:  Chin Med J (Engl)       Date:  2009-04-20       Impact factor: 2.628

7.  [Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with Ulinastatin and Maipuxin].

Authors:  Hong-yuan Lin
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2007-02-13

8.  [The effect of ulinastatin on disbalance of inflammation and immune status in patients with severe sepsis].

Authors:  Tie-jun Wu; Li-na Zhang; Cui-cui Kang
Journal:  Zhonghua Wei Zhong Bing Ji Jiu Yi Xue       Date:  2013-04

Review 9.  Ulinastatin for acute lung injury and acute respiratory distress syndrome: A systematic review and meta-analysis.

Authors:  Yu-Xin Leng; Shu-Guang Yang; Ya-Han Song; Xi Zhu; Gai-Qi Yao
Journal:  World J Crit Care Med       Date:  2014-02-04

10.  Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study.

Authors:  Dilip R Karnad; Rakesh Bhadade; Pradeep K Verma; Nivedita D Moulick; Mradul K Daga; Neelima D Chafekar; Shivakumar Iyer
Journal:  Intensive Care Med       Date:  2014-04-16       Impact factor: 17.440
View more
  19 in total

1.  Inter-α inhibitor proteins maintain neutrophils in a resting state by regulating shape and reducing ROS production.

Authors:  Soe Soe Htwe; Hidenori Wake; Keyue Liu; Kiyoshi Teshigawara; Barbara S Stonestreet; Yow-Pin Lim; Masahiro Nishibori
Journal:  Blood Adv       Date:  2018-08-14

2.  Ulinastatin attenuates LPS-induced inflammation in mouse macrophage RAW264.7 cells by inhibiting the JNK/NF-κB signaling pathway and activating the PI3K/Akt/Nrf2 pathway.

Authors:  Si-Tong Li; Qi Dai; Shu-Xian Zhang; Ya-Jun Liu; Qiu-Qiong Yu; Fei Tan; Shu-Hong Lu; Quan Wang; Jian-Wen Chen; He-Qing Huang; Pei-Qing Liu; Min Li
Journal:  Acta Pharmacol Sin       Date:  2018-01-11       Impact factor: 6.150

3.  Urinary trypsin inhibitor attenuates LPS-induced endothelial barrier dysfunction by upregulation of vascular endothelial-cadherin expression.

Authors:  Jie Chen; Jun Wang; Chenglei Su; Wenyi Qian; Li Sun; Hao Sun; Junjie Chen; Huazhong Zhang; Jinsong Zhang
Journal:  Inflamm Res       Date:  2015-12-17       Impact factor: 4.575

4.  Ulinastatin protects against acetaminophen-induced liver injury by alleviating ferroptosis via the SIRT1/NRF2/HO-1 pathway.

Authors:  Cong Wang; Tong Liu; Yingmu Tong; Ruixia Cui; Kai Qu; Chang Liu; Jingyao Zhang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

5.  Exogenous inter-α inhibitor proteins prevent cell death and improve ischemic stroke outcomes in mice.

Authors:  Louise D McCullough; Meaghan Roy-O'Reilly; Yun-Ju Lai; Anthony Patrizz; Yan Xu; Juneyoung Lee; Aleah Holmes; Daniel C Kraushaar; Anjali Chauhan; Lauren H Sansing; Barbara S Stonestreet; Liang Zhu; Julia Kofler; Yow-Pin Lim; Venugopal Reddy Venna
Journal:  J Clin Invest       Date:  2021-09-01       Impact factor: 14.808

6.  Inhibition of Fibroblast Growth Factor Receptor by AZD4547 Protects Against Inflammation in Septic Mice.

Authors:  Yueyue Huang; Fen Wang; Hao Li; ShunYao Xu; Wenwei Xu; XiaoJun Pan; Yufeng Hu; Lingjie Mao; Songzan Qian; Jingye Pan
Journal:  Inflammation       Date:  2019-12       Impact factor: 4.657

Review 7.  Auxiliary activation of the complement system and its importance for the pathophysiology of clinical conditions.

Authors:  Markus Huber-Lang; Kristina N Ekdahl; Rebecca Wiegner; Karin Fromell; Bo Nilsson
Journal:  Semin Immunopathol       Date:  2017-09-12       Impact factor: 9.623

8.  Glabridin attenuates lipopolysaccharide-induced acute lung injury by inhibiting p38MAPK/ERK signaling pathway.

Authors:  Li-Peng Zhang; Yan Zhao; Guo-Juan Liu; Da-Gang Yang; Yi-Huan Dong; Li-Hua Zhou
Journal:  Oncotarget       Date:  2017-03-21

9.  ADJunctive Ulinastatin in Sepsis Treatment in China (ADJUST study): study protocol for a randomized controlled trial.

Authors:  Wei Jiang; Xiangyou Yu; Tongwen Sun; Yanfen Chai; Ping Chang; Zhongqing Chen; Jingye Pan; Zhiyong Peng; Ruilan Wang; Xiaozhi Wang; Yuan Xu; Li Yu; Qingshan Zheng; Bin Du
Journal:  Trials       Date:  2018-02-21       Impact factor: 2.279

10.  Efficacy and Safety of Xuebijing Injection Combined With Ulinastatin as Adjunctive Therapy on Sepsis: A Systematic Review and Meta-Analysis.

Authors:  Guochao Chen; Yanyan Gao; Yue Jiang; Fei Yang; Shuangshuang Li; Di Tan; Qun Ma
Journal:  Front Pharmacol       Date:  2018-07-24       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.